Inclusion Criteria:

          -  Male or female patients aged ≥18 years

          -  Eastern Cooperative Oncology Group (ECOG) performance status of 0 to 2 and Life
             expectancy of at least 12 weeks

          -  Patients are able and willing to provide bone marrow biopsies/aspirates as requested
             by the protocol

          -  Patients with confirmed advanced hematological malignancies

          -  Negative serum pregnancy test

          -  Women and men of reproductive potential must agree to use highly effective
             contraception when sexually active.

          -  Ability to understand and the willingness to sign a written informed consent.

          -  Patients must have adequate coagulation (international normalized ratio (INR) or
             prothrombin time (PT), partial thromboplastin time (PTT) ≤1.5 times ULN)

          -  Adequate liver function (total bilirubin ≤ 1.5 times the ULN, alanine aminotransferase
             (ALT) and aspartate aminotransferase (AST) ≤ 2.5 times ULN

        Exclusion Criteria:

          -  Presence of active/uncontrolled central nervous system involvement

          -  History of clinically significant cardiac disease; uncontrolled hypertension

          -  Left ventricular ejection fraction (LVEF) < 45%

          -  Allogeneic stem cell transplant within 100 days before first dose of study drug

          -  Known history of human immunodeficiency virus (HIV) infection

          -  Chronic or active hepatitis B or C, requiring antiviral therapy

          -  Evidence of history of bleeding disorder, dialysis, or coexisting cancer that is
             distinct in primary site or histology from the cancer evaluated in this study

          -  Serious, uncontrolled infection

          -  Unresolved chronic toxicity > grade 1 from prior therapy

          -  Use of strong CYP3A4 inhibitors or strong inducers within 7 days prior to the start of
             study treatment and for the duration of the study